CNBC Africa | Closing Bell
Aspen’s operational performance was unpacked including action taken to pull back in Russia and China while growing the business. With more than 50% sterile capacity available, the single biggest opportunity relates to diabetic drugs with third-party manufacture and commercialisation agreements concluded for global supply outside the American and European markets.
Stephen Saad | Nastassia Arendse